Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sosei Group ( (JP:4565) ) has issued an update.
Nxera Pharma reported a sharp year-on-year jump in first-quarter revenue to ¥11.26 billion, up 69.4%, driven by stronger business performance that lifted core operating profit to ¥5.50 billion from a loss a year earlier. The company swung to a net profit attributable to owners of the parent of ¥1.79 billion, improving earnings per share to ¥19.82 and strengthening its equity ratio to 47.8% as total equity rose to ¥63.69 billion.
Despite the return to profitability, Nxera maintained its no-dividend stance and left its full-year 2026 guidance unchanged, projecting revenue between ¥33.8 billion and ¥48.8 billion and operating profit between ¥0.7 billion and ¥15.7 billion. The stable forecast and improved balance sheet suggest growing confidence in the company’s underlying business, while the continued focus on reinvestment over shareholder payouts signals a priority on funding future growth in its pharma pipeline and partnerships.
The most recent analyst rating on (JP:4565) stock is a Buy with a Yen1400.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.
More about Sosei Group
Nxera Pharma Co., Ltd. is a Tokyo Stock Exchange–listed biopharmaceutical company focused on drug discovery and development. The group generates revenue through partnered programs and licensing deals, and it reports under IFRS, emphasizing core operating profit as a measure of recurring cash-generating capability.
Average Trading Volume: 903,728
Technical Sentiment Signal: Hold
Current Market Cap: Yen87.87B
For detailed information about 4565 stock, go to TipRanks’ Stock Analysis page.